Liver Transplantation for Patients with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection with Special Reference to Hemophiliac Recipients in Japan

Access this Article

Search this Article

Author(s)

    • EGUCHI SUSUMU
    • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences
    • SOYAMA AKIHIKO
    • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences
    • HIDAKA MASAAKI
    • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences
    • MURAOKA IZUMI
    • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences
    • TOMONAGA TETSUO
    • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences
    • KANEMATSU TAKASHI
    • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences

Abstract

Liver transplantation for patients with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) remains challenging. The advent of highly active antiretroviral therapy (HAART) for HIV has reduced mortality from opportunistic infection related to acquired immunodeficiency syndrome dramatically, while about 50% of patients die of end-stage liver cirrhosis resulting from HCV. In Japan, liver cirrhosis frequently develops after HCV-HIV coinfection resulting from previously transfused infected blood products for hemophilia. The problems of liver transplantation for those patients arise from the need to control calcineurin inhibitor with HAART drugs, the difficulty of using interferon after liver transplantation with HAART, and the need to control intraoperative coagulopathy associated with hemophilia. We review published reports of liver transplantation for these patients in the updated world literature.

Journal

  • Surgery Today

    Surgery Today 41(10), 1325-1331, 2011-10-01

    Springer Verlag

References:  58

Cited by:  3

Codes

Page Top